New hope for kids with tough leukemia: drug combo trial launches
NCT ID NCT07156435
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a combination of two chemotherapy drugs—Vyxeos (a liposomal form of daunorubicin and cytarabine) and clofarabine—in 25 children and young adults (ages 1-21) with relapsed or refractory acute myeloid leukemia (AML). The main goal is to find the safest dose of this combination. Researchers hope it will be effective against leukemia that has come back or not responded to standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vyxeos (liposomal daunorubicin and cytarabine) combined with clofarabine
What this could lead to
If successful, this could lead to a new treatment option for children with hard-to-treat AML, potentially improving remission rates.
What could go wrong
This is a very early, small Phase 1 trial (25 children) focused on finding the right dose. It may not work as hoped, and side effects like infections are a known risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Berlin
RECRUITINGBerlin, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clinica Pediatrica Fondazione MBBM
RECRUITINGMonza, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Infantil Universitario Niño Jesús
RECRUITINGMadrid, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Sant Joan de Déu
RECRUITINGBarcelona, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Vall D'Hebron
RECRUITINGBarcelona, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale Pediatrico Bambino Gesu (OPBG)
RECRUITINGRoma, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Maxima Center
RECRUITINGUtrecht, Utrecht, 3584 CS, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rigshospitalet
RECRUITINGCopenhagen, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Anna Kinderspital
RECRUITINGVienna, Austria
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Children´s Hospital III Essen
RECRUITINGEssen, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsklinikum Augsburg
RECRUITINGAugsburg, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Frankfurt
RECRUITINGFrankfurt, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Hamburg-Eppendorf
RECRUITINGHamburg, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••